Drugs / RGT-61159
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06462183 | Aug 2024 → Dec 2025 overdue | adenoid cystic carcinoma, colorectal cancer | Rgenta Therapeutics Inc | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGT-61159 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06462183 ↗ |
| Action | Inhibit | “MYB inhibitor” NCT06462183 ↗ |
| Modality | Small molecule | “small molecule MYB inhibitor” NCT06462183 ↗ |
| Route | Oral | “RGT-61159 is an oral, small molecule MYB inhibitor.” NCT06462183 ↗ |
| Target | MYB | “small molecule MYB inhibitor” NCT06462183 ↗ |